1. Home
  2. REKR vs BMEA Comparison

REKR vs BMEA Comparison

Compare REKR & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rekor Systems Inc.

REKR

Rekor Systems Inc.

N/A

Current Price

$0.34

Market Cap

91.7M

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

N/A

Current Price

$1.44

Market Cap

92.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
REKR
BMEA
Founded
2017
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.7M
92.1M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
REKR
BMEA
Price
$0.34
$1.44
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $7.00
AVG Volume (30 Days)
1.6M
★ 1.7M
Earning Date
11-12-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
4.35
★ 69.19
EPS
★ N/A
N/A
Revenue
★ $9,234,000.00
N/A
Revenue This Year
$5.38
N/A
Revenue Next Year
$16.68
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.30
$0.87
52 Week High
$3.42
$2.24

Technical Indicators

Market Signals
Indicator
REKR
BMEA
Relative Strength Index (RSI) 24.23 48.32
Support Level N/A $1.23
Resistance Level $0.74 $1.47
Average True Range (ATR) 0.03 0.11
MACD -0.00 -0.01
Stochastic Oscillator 13.86 39.29

Price Performance

Historical Comparison
REKR
BMEA

About REKR Rekor Systems Inc.

Rekor Systems Inc is a roadway intelligence company focused on modernizing public safety, urban mobility, and transportation management through solutions. The company delivers services and solutions that collect, connect, and organize mobility data, providing real-time insights to support decision making, enhance situational awareness, enable rapid response, and support predictive analytics. The Company derives its revenues mainly from the licensing and sale of its roadway data and traffic management product and service offerings. These offerings include a mixture of data collection, implementation, engineering, customer support, and maintenance services, as well as software and hardware. The company operates in the United States and other regions.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: